Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

The approval in 2011 by the US Food and Drug Administration of the first cytotoxic T lymphocyte protein 4 (CTLA-4) antagonistic antibody, Bristol-Myers Squibb’s ipilimumab, for the treatment of ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

Five patients received the vaccine with subcutaneous ipilimumab (Yervoy, Bristol Myers Squibb), an anti-CTLA-4 antibody, and four received only the vaccine. Safety and tolerability served as the ...

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

The study randomly assigned 42 patients (one would later withdraw consent) to three immunotherapy treatment arms: nivolumab alone, nivolumab plus ipilimumab ... while the CTLA-4 protein was ...